Furthermore, we developed an in vitro model of IBD utilizing LPS-stimulated Caco-2 cells to evaluate the possible therapeutic effects of genetic or pharmacological inhibition of ACSL4 on intestinal epithelial cell dysfunction. This evidence concerns the gene ACSL4 and inflammatory bowel disease.